NEOGEN CORP
10-K, EX-27, 2000-08-14
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: NEOGEN CORP, 10-K, EX-23, 2000-08-14
Next: NEOGEN CORP, 8-K/A, 2000-08-14



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM (A)
CONSOLIDATED BALANCE SHEET AND CONSOLIDATED STATEMENTS OF INCOME AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          MAY-31-2000
<PERIOD-START>                             JUN-01-1999
<PERIOD-END>                               MAY-31-2000
<CASH>                                       2,198,189
<SECURITIES>                                 8,471,740
<RECEIVABLES>                                5,237,692
<ALLOWANCES>                                   361,000
<INVENTORY>                                  5,393,017
<CURRENT-ASSETS>                            21,601,839
<PP&E>                                       6,860,578
<DEPRECIATION>                               4,205,333
<TOTAL-ASSETS>                              29,528,441
<CURRENT-LIABILITIES>                        3,337,379
<BONDS>                                              0
                                0
                                          0
<COMMON>                                       923,710
<OTHER-SE>                                  24,880,136
<TOTAL-LIABILITY-AND-EQUITY>                29,528,441
<SALES>                                     23,512,018
<TOTAL-REVENUES>                            23,512,018
<CGS>                                       10,860,468
<TOTAL-COSTS>                               21,149,447
<OTHER-EXPENSES>                           (1,933,046)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              12,106
<INCOME-PRETAX>                              4,283,511
<INCOME-TAX>                                 1,210,000
<INCOME-CONTINUING>                          3,073,511
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 3,073,511
<EPS-BASIC>                                        .52
<EPS-DILUTED>                                      .52


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission